Marker Therapeutics, Inc.

Daily Archives: Tuesday, August 6, 2019

Marker Therapeutics Appoints Steve Elms to its Board of Directors

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Steve Elms, to its Board of Directors, effective August 6.
Read More